Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells

Authors: Michele Navarra, Marilena Celano, Jessica Maiuolo, Silvia Schenone, Maurizio Botta, Adriano Angelucci, Placido Bramanti, Diego Russo

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Neuroblastoma (NB) is the second most common solid malignancy of childhood that usually undergoes rapid progression with a poor prognosis upon metastasis. The Src-family tyrosine kinases (SFKs) are a group of proteins involved in cancer development and invasiveness that seem to play an important role in the NB carcinogenesis.

Methods

To determine cell proliferation, the growth rate was evaluated by both MTT test and cells counted. Analysis of DNA content was performed for the evaluation of the cell cycle and apoptosis. To characterize the mechanisms underlying the antiproliferative effects induced by SI 34, a novel pyrazolo-pyrimidine derivative provided with Src inhibitory activity, the involvement of some cellular pathways that are important for cell proliferation and survival was investigated by western blot assays. In particular, the contribution of cyclins, Src and ERK were examined. Finally, experiments of cell adhesion and invasiveness were performed.

Results

Treatment of SH-SY5Y human NB cells and CHP100 human neuroepithelioma (NE) cultures with three novel pyrazolo[3,4-d]pyrimidine derivatives, namely SI 34, SI 35 and SI 83, inhibits the cell proliferation in a time and concentration-dependent manner. The maximal effect was obtained after 72 hours incubation with SI 34 10 μM. Fluorescence microscopy experiments, flow cytometry analysis and determination of caspase-3 activity by fluorimetric assays showed that SI 34 induced SH-SY5Y apoptosis. Moreover, SI 34 determined cell cycle arrest at the G0/G1 phase, paralleled by a decreased expression of cyclin D1. Furthermore, our data indicate that SI 34 reduces the SH-SY5Y cells adhesion and invasiveness. Evidence that SI 34 inhibits the Src and the ERK-phosphorylation, suggests the mechanism through which it exerts its effects in SH-SY5Y cells.

Conclusions

Our study shows the ability of this pyrazolo-pyrimidine Src inhibitor in reducing the growth and the invasiveness of human NB cells, suggesting a promising role as novel drug in the treatment of neuroblastoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003, 3: 203-216. 10.1038/nrc1014.CrossRefPubMed Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003, 3: 203-216. 10.1038/nrc1014.CrossRefPubMed
2.
go back to reference Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-2120. 10.1016/S0140-6736(07)60983-0.CrossRefPubMed Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-2120. 10.1016/S0140-6736(07)60983-0.CrossRefPubMed
3.
go back to reference Levitzki A: Tyrosine kinases as targets for cancer therapy. Eur J Cancer. 2002, 38 (Suppl 5): S11-18. 10.1016/S0959-8049(02)80598-6.CrossRefPubMed Levitzki A: Tyrosine kinases as targets for cancer therapy. Eur J Cancer. 2002, 38 (Suppl 5): S11-18. 10.1016/S0959-8049(02)80598-6.CrossRefPubMed
4.
go back to reference Krause DS, Van Etten RA: Tyrosine Kinases as Targets for Cancer Therapy. N Engl J Med. 2005, 353: 172-187. 10.1056/NEJMra044389.CrossRefPubMed Krause DS, Van Etten RA: Tyrosine Kinases as Targets for Cancer Therapy. N Engl J Med. 2005, 353: 172-187. 10.1056/NEJMra044389.CrossRefPubMed
5.
go back to reference Arora A, Scholar EM: Role of Tyrosine Kinase Inhibitors in Cancer Therapy. JPE. 2005, 315: 971-979. 10.1124/jpet.105.084145. Arora A, Scholar EM: Role of Tyrosine Kinase Inhibitors in Cancer Therapy. JPE. 2005, 315: 971-979. 10.1124/jpet.105.084145.
6.
go back to reference Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I: Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009, 9 (1): 66-76.CrossRefPubMed Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I: Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009, 9 (1): 66-76.CrossRefPubMed
7.
go back to reference Parsons SJ, Parsons JT: Src family kinases, key regulators of signal transduction. Oncogene. 2004, 23: 7906-7909. 10.1038/sj.onc.1208160.CrossRefPubMed Parsons SJ, Parsons JT: Src family kinases, key regulators of signal transduction. Oncogene. 2004, 23: 7906-7909. 10.1038/sj.onc.1208160.CrossRefPubMed
8.
go back to reference Alvarez RH, Kantarjian HM, Cortes JE: The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006, 107 (8): 1918-1929. 10.1002/cncr.22215.CrossRefPubMed Alvarez RH, Kantarjian HM, Cortes JE: The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006, 107 (8): 1918-1929. 10.1002/cncr.22215.CrossRefPubMed
9.
go back to reference Brunton VG, Frame MC: Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008, 8: 427-432. 10.1016/j.coph.2008.06.012.CrossRefPubMed Brunton VG, Frame MC: Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008, 8: 427-432. 10.1016/j.coph.2008.06.012.CrossRefPubMed
10.
go back to reference Grant S, Dent P: Kinase inhibitors and cytotoxic drug resistance. Clin Cancer Res. 2004, 10 (7): 2205-2207. 10.1158/1078-0432.CCR-0001-4.CrossRefPubMed Grant S, Dent P: Kinase inhibitors and cytotoxic drug resistance. Clin Cancer Res. 2004, 10 (7): 2205-2207. 10.1158/1078-0432.CCR-0001-4.CrossRefPubMed
11.
go back to reference Johnson FM, Gallick GE: Src Family nonreceptor tyrosine kinases as molecular targets for cancer terapy. Anticancer Agents Med Chem. 2007, 7: 651-659. 10.2174/187152007784111278.CrossRefPubMed Johnson FM, Gallick GE: Src Family nonreceptor tyrosine kinases as molecular targets for cancer terapy. Anticancer Agents Med Chem. 2007, 7: 651-659. 10.2174/187152007784111278.CrossRefPubMed
12.
go back to reference Mellström K, Bjelfman C, Hammerling U, Påhlman S: Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation. Mol Cell Biol. 1987, 7: 4178-4184.CrossRefPubMedPubMedCentral Mellström K, Bjelfman C, Hammerling U, Påhlman S: Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation. Mol Cell Biol. 1987, 7: 4178-4184.CrossRefPubMedPubMedCentral
13.
go back to reference Bjelfman C, Hedborg F, Johansson I, Nordenskjold M, Palhlman S: Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis. Cancer Res. 1990, 50: 6908-6914.PubMed Bjelfman C, Hedborg F, Johansson I, Nordenskjold M, Palhlman S: Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis. Cancer Res. 1990, 50: 6908-6914.PubMed
14.
go back to reference Carraro F, Pucci A, Naldini A, Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, Menozzi G, Mosti L, Manetti F, Botta M: Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem. 2004, 47: 1595-1598. 10.1021/jm034257u.CrossRefPubMed Carraro F, Pucci A, Naldini A, Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, Menozzi G, Mosti L, Manetti F, Botta M: Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem. 2004, 47: 1595-1598. 10.1021/jm034257u.CrossRefPubMed
15.
go back to reference Schenone S, Bruno O, Bondavalli F, Ranise A, Mosti L, Menozzi G, Fossa P, Donnini S, Santoro A, Ziche M, Manetti F, Botta M: Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur J Med Chem. 2004, 39: 939-946. 10.1016/j.ejmech.2004.07.010.CrossRefPubMed Schenone S, Bruno O, Bondavalli F, Ranise A, Mosti L, Menozzi G, Fossa P, Donnini S, Santoro A, Ziche M, Manetti F, Botta M: Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur J Med Chem. 2004, 39: 939-946. 10.1016/j.ejmech.2004.07.010.CrossRefPubMed
16.
go back to reference Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M: Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem. 2007, 50: 5579-5588. 10.1021/jm061449r.CrossRefPubMed Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M: Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem. 2007, 50: 5579-5588. 10.1021/jm061449r.CrossRefPubMed
17.
go back to reference Angelucci A, Schenone S, Gravina GL, Muzi P, Festuccia C, Vicentini C, Botta M, Bologna M: Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer. 2006, 42: 2838-2845. 10.1016/j.ejca.2006.06.024.CrossRefPubMed Angelucci A, Schenone S, Gravina GL, Muzi P, Festuccia C, Vicentini C, Botta M, Bologna M: Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer. 2006, 42: 2838-2845. 10.1016/j.ejca.2006.06.024.CrossRefPubMed
18.
go back to reference Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D: Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest. 2007, 30: RC31-34.CrossRefPubMed Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D: Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest. 2007, 30: RC31-34.CrossRefPubMed
19.
go back to reference Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D: Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer. 2008, 15: 499-510. 10.1677/ERC-07-0243.CrossRefPubMed Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D: Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer. 2008, 15: 499-510. 10.1677/ERC-07-0243.CrossRefPubMed
20.
go back to reference Rossi A, Schenone S, Angelucci A, Cozzi M, Caracciolo V, Pentimalli F, Puca A, Pucci B, La Montagna R, Bologna M, Botta M, Giordano A: New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J. 2010, 24 (8): 2881-2892. 10.1096/fj.09-148593.CrossRefPubMedPubMedCentral Rossi A, Schenone S, Angelucci A, Cozzi M, Caracciolo V, Pentimalli F, Puca A, Pucci B, La Montagna R, Bologna M, Botta M, Giordano A: New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB J. 2010, 24 (8): 2881-2892. 10.1096/fj.09-148593.CrossRefPubMedPubMedCentral
21.
go back to reference Thiele CJ, McKeon C, Triche TJ, Ross RA, Reynolds CP, Israel MA: Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J Clin Invest. 1987, 80 (3): 804-811. 10.1172/JCI113137.CrossRefPubMedPubMedCentral Thiele CJ, McKeon C, Triche TJ, Ross RA, Reynolds CP, Israel MA: Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J Clin Invest. 1987, 80 (3): 804-811. 10.1172/JCI113137.CrossRefPubMedPubMedCentral
22.
go back to reference Navarra M, Romano C, Lorenzon T, Rotiroti D, Di Renzo G: Ethanol exposure inhibits the cytotoxic effect induced by gp120 in CHP100 human neuroblastoma cells. J Neurosci Res. 2001, 65: 354-361. 10.1002/jnr.1161.CrossRefPubMed Navarra M, Romano C, Lorenzon T, Rotiroti D, Di Renzo G: Ethanol exposure inhibits the cytotoxic effect induced by gp120 in CHP100 human neuroblastoma cells. J Neurosci Res. 2001, 65: 354-361. 10.1002/jnr.1161.CrossRefPubMed
23.
go back to reference Corasaniti MT, Maiuolo J, Maida S, Fratto V, Navarra M, Russo R, Amantea D, Morrone LA, Bagetta G: Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. Br J Pharmacol. 2007, 151: 518-529. 10.1038/sj.bjp.0707237.CrossRefPubMedPubMedCentral Corasaniti MT, Maiuolo J, Maida S, Fratto V, Navarra M, Russo R, Amantea D, Morrone LA, Bagetta G: Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. Br J Pharmacol. 2007, 151: 518-529. 10.1038/sj.bjp.0707237.CrossRefPubMedPubMedCentral
24.
go back to reference Corasaniti MT, Navarra M, Catani MV, Melino G, Nisticò G, Finazzi-Agrò A: NMDA and HIV-1 coat protein, GP120, produce necrotic but not apoptotic cell death in human CHP100 neuroblastoma cultures via a mechanism involving calpain. Biochem Biophys Res Commun. 1996, 229: 299-304. 10.1006/bbrc.1996.1796.CrossRefPubMed Corasaniti MT, Navarra M, Catani MV, Melino G, Nisticò G, Finazzi-Agrò A: NMDA and HIV-1 coat protein, GP120, produce necrotic but not apoptotic cell death in human CHP100 neuroblastoma cultures via a mechanism involving calpain. Biochem Biophys Res Commun. 1996, 229: 299-304. 10.1006/bbrc.1996.1796.CrossRefPubMed
25.
go back to reference Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN: Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res. 2008, 68: 2599-2609. 10.1158/0008-5472.CAN-07-5032.CrossRefPubMed Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJ, Versteeg R, Caron HN: Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res. 2008, 68: 2599-2609. 10.1158/0008-5472.CAN-07-5032.CrossRefPubMed
26.
go back to reference Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 2004, 96: 46-55. 10.1093/jnci/djh004.CrossRefPubMed Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 2004, 96: 46-55. 10.1093/jnci/djh004.CrossRefPubMed
27.
go back to reference Meco D, Riccardi A, Servidei T, Brueggen J, Gessi M, Riccardi R, Dominici C: Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett. 2005, 228: 211-209. 10.1016/j.canlet.2005.02.054.CrossRefPubMed Meco D, Riccardi A, Servidei T, Brueggen J, Gessi M, Riccardi R, Dominici C: Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett. 2005, 228: 211-209. 10.1016/j.canlet.2005.02.054.CrossRefPubMed
28.
go back to reference Timeus F, Crescenzio N, Fandi A, Doria A, Foglia L, Cordero di Montezemolo L: In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep. 2008, 19: 353-359.PubMed Timeus F, Crescenzio N, Fandi A, Doria A, Foglia L, Cordero di Montezemolo L: In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep. 2008, 19: 353-359.PubMed
29.
go back to reference Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschellà G, Dominici C: Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int J Cancer. 2009, 125: 2547-2555. 10.1002/ijc.24606.CrossRefPubMed Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschellà G, Dominici C: Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int J Cancer. 2009, 125: 2547-2555. 10.1002/ijc.24606.CrossRefPubMed
30.
go back to reference Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008, 50: 254-258. 10.1002/pbc.21132.CrossRefPubMed Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008, 50: 254-258. 10.1002/pbc.21132.CrossRefPubMed
31.
go back to reference Schenone S, Manetti F, Botta M: Last findings on dual inhibitors of abl and SRC tyrosine-kinases. Mini Rev Med Chem. 2007, 7: 191-201. 10.2174/138955707779802598.CrossRefPubMed Schenone S, Manetti F, Botta M: Last findings on dual inhibitors of abl and SRC tyrosine-kinases. Mini Rev Med Chem. 2007, 7: 191-201. 10.2174/138955707779802598.CrossRefPubMed
32.
go back to reference Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K, Su MS, Zhao H, Cnaan A, Sakiyama S: High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 1997, 57 (20): 4578-4584.PubMed Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K, Su MS, Zhao H, Cnaan A, Sakiyama S: High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 1997, 57 (20): 4578-4584.PubMed
33.
go back to reference Schwab M, Westermann F, Hero B, Berthold F: Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003, 4: 472-480. 10.1016/S1470-2045(03)01166-5.CrossRefPubMed Schwab M, Westermann F, Hero B, Berthold F: Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003, 4: 472-480. 10.1016/S1470-2045(03)01166-5.CrossRefPubMed
34.
go back to reference Laird AD, Shalloway D: Oncoprotein signalling and mitosis. Cell Signal. 1997, 9: 249-255. 10.1016/S0898-6568(96)00176-3.CrossRefPubMed Laird AD, Shalloway D: Oncoprotein signalling and mitosis. Cell Signal. 1997, 9: 249-255. 10.1016/S0898-6568(96)00176-3.CrossRefPubMed
35.
go back to reference Brooks AJ, Wooh JW, Tunny KA, Waters MJ: Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol. 2008, 40: 1984-1989. 10.1016/j.biocel.2007.07.008.CrossRefPubMed Brooks AJ, Wooh JW, Tunny KA, Waters MJ: Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol. 2008, 40: 1984-1989. 10.1016/j.biocel.2007.07.008.CrossRefPubMed
36.
go back to reference Johnson DE: Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul. 2008, 48: 98-112. 10.1016/j.advenzreg.2007.11.002.CrossRefPubMed Johnson DE: Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul. 2008, 48: 98-112. 10.1016/j.advenzreg.2007.11.002.CrossRefPubMed
37.
go back to reference Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y: Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res. 2005, 11: 4321-4330. 10.1158/1078-0432.CCR-04-2071.CrossRefPubMed Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y: Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res. 2005, 11: 4321-4330. 10.1158/1078-0432.CCR-04-2071.CrossRefPubMed
38.
go back to reference Lee HP, Zhu X, Zhu X, Skidmore SC, Perry G, Sayre LM, Smith MA, Lee HG: The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells. J Neurochem. 2009, 108: 1434-1441. 10.1111/j.1471-4159.2009.05883.x.CrossRefPubMedPubMedCentral Lee HP, Zhu X, Zhu X, Skidmore SC, Perry G, Sayre LM, Smith MA, Lee HG: The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells. J Neurochem. 2009, 108: 1434-1441. 10.1111/j.1471-4159.2009.05883.x.CrossRefPubMedPubMedCentral
39.
go back to reference Cox BD, Natarajan M, Stettner MR, Gladson CL: New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006, 99 (1): 35-52. 10.1002/jcb.20956.CrossRefPubMed Cox BD, Natarajan M, Stettner MR, Gladson CL: New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006, 99 (1): 35-52. 10.1002/jcb.20956.CrossRefPubMed
Metadata
Title
Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells
Authors
Michele Navarra
Marilena Celano
Jessica Maiuolo
Silvia Schenone
Maurizio Botta
Adriano Angelucci
Placido Bramanti
Diego Russo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-602

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine